Valeant Pharmaceuticals completes sale of filler and toxin assets to Galderma

Valeant Pharmaceuticals International has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle SA, which recently completed its acquisition of Galderma.

"We are pleased to complete the divestiture of our products to a company that is firmly committed to the aesthetic dermatology market," said J. Michael Pearson, chairman and chief executive officer. 

"Humberto Antunes, CEO of Galderma, has embraced our commercial team and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry," added Mr Pearson.